Biocartis Group NV (BCART.BR)
| Previous close | 3.7100 |
| Open | 3.7000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.6200 - 3.7150 |
| 52-week range | 3.5550 - 4.9000 |
| Volume | |
| Avg. volume | 44,640 |
| Market cap | 208.315M |
| Beta (5Y monthly) | 1.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1120 |
| Earnings date | 01 Sept 2021 - 06 Sept 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Press release Biocartis Group NV: SeptiCyte® RAPID Receives 510(k) clearance by US FDA
PRESS RELEASE: 30 November 2021, 17:40 CET SeptiCyte® RAPID Receives 510(k) clearance by US FDA Mechelen, Belgium, 30 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that the US Food and Drug Administration (FDA) has granted 510(k) clearance1 for SeptiCyte® RAPID (CE-IVD, US FDA 510(k)). This test runs on Biocartis’ rapid and easy-to-use molecular diagnostics Idylla™ platform2 and was devel
- Globe Newswire
Press release Biocartis Group NV: New Study Demonstrates Idylla™ EGFR Mutation Test (CE-IVD) Shortens Time to Patient Management Decisions for Patients with Non-Small Cell Lung Cancer
PRESS RELEASE: 16 November 2021, 07:00 CET New Study Demonstrates Idylla™ EGFR Mutation Test (CE-IVD) Shortens Time to Patient Management Decisions for Patients with Non-Small Cell Lung Cancer Mechelen, Belgium, 16 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of a new study1 that demonstrates that the Idylla™ EGFR Mutation Test (CE-IVD) running on Biocartis’ molecular dia
- Globe Newswire
Press release Biocartis Group NV: Biocartis Q3 2021 Business Update
PRESS RELEASE: REGULATED INFORMATION10 November 2021, 07:00 CET BIOCARTIS Q3 2021 BUSINESS UPDATE Mechelen, Belgium, 10 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today provides a business update for the third quarter of 2021 and the outlook for remainder of the year 2021. Commenting on the Q3 2021 Business Update, Herman Verrelst, Chief Executive Officer of Biocartis, said: “During Q3 2021, customer
